ARID1A and cancer: Recurrent mutations in chromatin modifiers are most frequently occurring in many cancers, such as activating mutations in enhancer of zeste homolog 2 (EZH2) and inactivating mutations in CREB Binding Protein (CREBBP)/E1A binding protein P300 (EP300), lysine Methyltransferase 2D (KMT2D), SET domain containing 2 (SETD2), AT-rich interaction domain 1A (ARID1A), isocitrate dehydrogenase type 2(IDH2) (Cheng et al., 2019), suggesting that these epigenetic modifiers are ideal targets in therapeutic approaches.